The FDA Quality Management System Regulation (QMSR) took effect on February 2, 2026. It amends 21 CFR Part 820 to incorporate ISO 13485:2016, so FDA inspections of medical device manufacturers now assess compliance against ISO 13485 together with the FDA-specific provisions the rule retains.
What a company needs to do depends on whether it already holds ISO 13485 and MDSAP certification or has only ever worked to the legacy Part 820. There is no grace period beyond the effective date, and firms that are not aligned may be at increased risk during FDA inspections. All manufacturers marketing devices in the U.S. are affected, but the path to compliance looks very different depending on your starting point. Broadly, companies fall into one of two categories:
Understanding your starting point is critical to defining the right transition strategy. The sections below take each in turn, followed by the expectation that applies to both.
Under the QMSR, ISO 13485:2016 becomes the primary quality system framework for FDA compliance, incorporated into 21 CFR Part 820. Part 820 as previously written no longer applies. FDA retains certain FDA-specific requirements where necessary, including complaint handling, reporting, records, and enforcement provisions, so compliance means meeting ISO 13485 and the applicable FDA-specific provisions.
The goal of the change is to reduce regulatory burden, streamline global compliance, and improve consistency across jurisdictions. The rule is published as the final rule in the Federal Register. For how inspectors are applying it, see our analysis of FDA inspections in 2026.
A medical device manufacturer already certified to ISO 13485 and MDSAP is generally well positioned for QMSR, but compliance is not automatic. The work is to confirm and align the existing QMS, with FDA-specific requirements layered on top, rather than to redesign it. A targeted gap assessment and focused remediation is typically sufficient.
FDA expects ISO 13485:2016 to be the core QMS framework, much as MDSAP supplements ISO 13485 with regional requirements. Assumptions can create inspection risk. For the underlying framework, see our ISO 13485 certification consulting services.
Key recommended actions:
- Complaint handling and complaint files
- Medical Device Reporting (MDR, the FDA adverse event process) linkages
- Records retention and FDA inspection readiness
- Unique Device Identification (UDI), where applicable
- MDSAP already demonstrates how ISO 13485 requirements are supplemented by regional regulations.
- Treat the FDA QMSR similarly, as a regional overlay rather than a separate QMS.
- Risk management should not be limited to design and development.
- Confirm risk-based thinking is embedded across:
- Align risk management activities with ISO 14971 and link them clearly to QMS processes.
- Internal audits should explicitly assess QMSR alignment.
- Management review inputs should reflect risk, performance, and regulatory compliance across markets, including the U.S.
Closing gaps early limits disruption and inspection risk.
A medical device manufacturer whose quality system complies only with legacy 21 CFR Part 820 faces a substantial transformation under the QMSR, not a simple procedure update. The company must adopt ISO 13485:2016 as the foundation of its QMS and incorporate the FDA-specific QMSR requirements into it. Expect a structured implementation effort similar to preparing for initial ISO 13485 certification.
Key recommended actions
- Restructure the quality manual and process architecture around ISO 13485 clauses.
- Harmonize procedures to reflect ISO terminology, structure, and intent.
- Address gaps where ISO requirements go beyond legacy 21 CFR 820 expectations.
- Maintain FDA expectations related to:
- Embed FDA requirements in the ISO framework rather than managing them as standalone processes.
- ISO 13485 requires risk-based thinking across all QMS processes.
- Companies transitioning from 21 CFR 820 often need to expand risk management beyond product design.
- Apply risk management systematically to:
- Integrate risk management into design and development from concept through the lifecycle.
- Strengthen traceability between risks, design inputs, verification, validation, and post-market feedback.
Update training, audits, and management review
- Train personnel on ISO 13485 concepts and risk-based thinking.
- Redesign internal audit programs to ISO 13485 and QMSR criteria.
- Ensure management review addresses QMS performance, risks, and regulatory obligations together.
Implementing ISO 13485-aligned systems, embedding risk management, and demonstrating maturity takes time, so companies in this group should not wait.
Risk management integration across the entire quality system is a central expectation under both ISO 13485 and the QMSR. A medical device manufacturer cannot confine risk management to design and development; risk-based thinking has to run through every QMS process. This applies whether a company starts from ISO 13485 and MDSAP certification or from legacy 21 CFR 820.
The QMSR is a major regulatory milestone, harmonizing FDA requirements with the internationally recognized QMS standard used worldwide, but the path forward is not the same for every organization. The first step is to assess your current state and plan next steps.
Qserve's US FDA consulting team supports manufacturers with QMSR gap assessments and mock inspections, QMS procedure updates, and internal audit training.
Contact us to discuss your QMSR readiness.